Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522340 · ClinicalTrials.gov registry record · Phase 2
Exercise After an ICD
A Phase 2 study of Heart Failure, Congestive and Defibrillators, Implantable, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00522340 is a Phase 2 study of Heart Failure, Congestive and Defibrillators, Implantable that has completed, run by University of Washington. The registered enrollment target is 160 participants, below the 637-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00522340, a Phase 2 study of Heart Failure, Congestive and Defibrillators, Implantable, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
An implantable cardioverter-defibrillator (ICD) is a small device that is surgically implanted in the chest or abdomen and uses electrical pulses or shocks to help control life-threatening, irregular heartbeats. Increasing aerobic exercise may provide health benefits to people with ICDs. This study will examine the effects of an exercise program on heart and lung function in people who have an ICD.
Conditions Studied
Interventions
- BEHAVIORAL Aerobic Exercise Program
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00522340
The ClinicalTrials.gov registry entry for NCT00522340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 637-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (75% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which Aerobic Exercise Program is the first listed.
NCT00522340 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00522340 about?
NCT00522340 is a clinical study titled "Exercise After an ICD". An implantable cardioverter-defibrillator (ICD) is a small device that is surgically implanted in the chest or abdomen and uses electrical pulses or shocks to help control life-threatening, irregular heartbeats. Increasing aerobic exercise may provide health benefits to people with ICDs. This study ...
What is the current status of trial NCT00522340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-11. Estimated completion is 2014-06.
What conditions does trial NCT00522340 study?
This clinical trial studies the following conditions: Heart Failure, Congestive, Defibrillators, Implantable.
What interventions are being tested in trial NCT00522340?
The interventions under investigation include: Aerobic Exercise Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT00522340?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00522340 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
COMPLETED · Phase 2
-
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
COMPLETED · Phase 2
-
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
COMPLETED · Phase 2
-
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
COMPLETED · Phase 2
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.